Wei-Cheng Lu

Wei-Cheng Lu has extensive work experience in the field of biotechnology and therapeutics. Wei-Cheng is currently working as a Principal Scientist at Alloy Therapeutics, Inc. Previously, they worked as a Senior Scientist at Arbor Biotechnologies, where they were involved in the development and characterization of CRISPR nucleases. Prior to that, they served as a Scientific Consultant at Aeglea BioTherapeutics, collaborating with the R&D team to develop product candidates for enzyme depletion therapies. Wei-Cheng also worked as a Postdoctoral Fellow at The University of Texas at Austin, where they conducted research on therapeutic enzyme engineering and therapeutic applications. Throughout their career, Wei-Cheng Lu has been a co-inventor on multiple patent application families in the field of biotechnology.

Wei-Cheng Lu completed their Doctor of Philosophy (Ph.D.) in Biochemistry at The University of Texas at Austin in 2013. Wei-Cheng'sresearch focused on directed evolution and enzyme engineering for therapeutics.